Skip to main content
. 2011 Sep 20;108(40):16723–16728. doi: 10.1073/pnas.1110814108

Fig. 3.

Fig. 3.

Four types of NY-ESO-1 immunity integration were detected during ipilimumab treatment. (A) NY-ESO-1–specific CD4+ T-cell response before and after CTLA-4 blockade. (B) NY-ESO-1–specific CD8+ T-cell response before and after CTLA-4 blockade. Category I, 11 of 20 patients had NY-ESO-1–specific CD4+ and CD8+ T-cell response; category II, two of 20 patients had CD8 T-cell response; category III, five of 20 patients had CD4+ T-cell response; and category IV, two of 20 patients had neither CD4+ nor CD8 T-cell response.